Abstracts tagged "growth factors and systemic sclerosis"

Abstract Number: 651 • 2013 ACR/ARHP Annual Meeting
Growth Differentation Factor-15, a Marker Of lung disease In Systemic Sclerosis, Is Involved In Fibrosis Development But Does Not Impair Fibrosis Development
Stijn Lambrecht¹, Vanessa Smith², Katelijne De wilde³, Julie Coudenys⁴, Filip De Keyser² and Dirk Elewaut⁵, ¹Dept of Rheumatology, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Deptartment of Rheumatology, Ghent University, Ghent, Belgium, ⁴Dept of Rheumatology, Ghent University, Ghent, Belgium, ⁵Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: It is generally known that members of the TGF-β superfamily are involved in the regulation of connective tissue biology in systemic sclerosis (SSc). Growth…
Abstract Number: 2291 • 2012 ACR/ARHP Annual Meeting
Enhanced Release of S100A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis
Joanna Nikitorowicz Buniak¹, Christopher P. Denton¹, David J. Abraham² and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²UCL Medical School, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a severe disease of unknown aetiology characterised by cellular injury and activation in early stage, followed by autoimmunity and fibrosis.…
Abstract Number: 704 • 2012 ACR/ARHP Annual Meeting
Decreased Number of Endothelial Progenitor Cells in Systemic Sclerosis Patients with Early Disease
Fernando V. Andrigueti, Maria I. Arismendi, Pâmela C.C. Ebbing and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Microangiopathy and endothelial dysfunction are present in early phases of Systemic sclerosis (SSc), resulting in decreased blood flow and tissue ischemia. Several mechanisms including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].